Finke, Juergen and Schmoor, Claudia and Bethge, Wolfgang A. and Ottinger, Hellmut D. and Stelljes, Matthias and Zander, Axel R. and Volin, Liisa and Heim, Dominik A. and Schwerdtfeger, Rainer and Kolbe, Karin and Mayer, Jiri and Maertens, Johan A. and Linkesch, Werner and Holler, Ernst and Koza, Vladimir and Bornhaeuser, Martin and Einsele, Hermann and Bertz, Hartmut and Grishina, Olga and Socie, Gerard (2012) Prognostic Factors Affecting Outcome after Allogeneic Transplantation for Hematological Malignancies from Unrelated Donors: Results from a Randomized Trial. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 18 (11). pp. 1716-1726. ISSN 1083-8791,
Full text not available from this repository. (Request a copy)Abstract
Several prognostic factors for the outcome after allogeneic hematopoietic stem-cell transplant (HSCT) from matched unrelated donors have been postulated from registry data; however, data from randomized trials are lacking. We present analyses on the effects of patient-related, donor-related, and treatment-related prognostic factors on acute GVHD (aGVHD), chronic GVHD (cGVHD), relapse, nonrelapse mortality (NRM), disease-free survival (DFS), and overall survival (OS) in a randomized, multicenter, open-label, phase III trial comparing standard graft-versus-host-disease (GVHD) prophylaxis with and without pretransplantation ATG-Fresenius (ATG-F) in 201 adult patients receiving myeloablative conditioning before HSCT from HLA-A, HLA-B antigen, HLA-DRBI, HLA-DQBI allele matched unrelated donors. High-resolution testing (allele) of HLA-A, HLA-B, and HLA-C were obtained after study closure, and the impact of an HLA 10/10 4-digit mismatch on outcome and on the treatment effect of ATG-F versus control investigated. Advanced disease was a negative factor for relapse, DFS, and OS. Donor age >= 40 adversely affected the risk of aGVHD III-IV, extensive cGVHD, and OS. Younger donors are to be preferred in unrelated donor transplantation. Advanced disease patients need special precautions to improve outcome. The degree of mismatch had no major influence on the positive effect of ATG-F on the reduction of aGVHD and cGVHD. Biol Blood Marrow Transplant 18: 1716-1726 (2012) (C) 2012 American Society for Blood and Marrow Transplantation
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | STEM-CELL TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; VERSUS-HOST-DISEASE; LONG-TERM SURVIVAL; MARROW TRANSPLANTATION; RISK-FACTORS; BONE-MARROW; PROPHYLAXIS; RECIPIENT; GLOBULIN; Allogeneic hematopoietic stem-cell transplantation; Graft-versus-host-disease prophylaxis; HLA-matching |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 05 May 2020 04:41 |
| Last Modified: | 05 May 2020 04:41 |
| URI: | https://pred.uni-regensburg.de/id/eprint/17852 |
Actions (login required)
 |
View Item |
